Last update 08 May 2025

Anti-thymocyte Globulin (Rabbit)

Overview

Basic Info

Drug Type
Immunoglobulin
Synonyms
Anti-human thymocyteimmunoglobulin, Rabbit, Thymoglobulin, Thymoglobuline
+ [2]
Target-
Action
inhibitors
Mechanism
Thymocyte inhibitors
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
RegulationOrphan Drug (United States)
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Graft Rejection
Japan
22 Apr 2011
Bacterial Infections
Australia
18 Jul 2008
Graft vs Host Disease
Japan
16 Jul 2008
Anemia, Aplastic
South Korea
19 Jan 1993
Cardiac transplant rejection
South Korea
19 Jan 1993
Renal transplant rejection
South Korea
19 Jan 1993
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Death, Sudden, CardiacPhase 2
United Kingdom
01 Jan 2011
Reperfusion InjuryPhase 2
United Kingdom
01 Jan 2011
Chronic graft-versus-host diseasePhase 2
Canada
01 Apr 2010
LeukemiaPhase 2
Canada
01 Apr 2010
Lung transplant rejectionPhase 2
United States
01 Jan 2006
Primary Graft DysfunctionPhase 2
United States
01 Jan 2006
Acute rejection of renal transplantPhase 2
France
01 May 2000
Acute rejection of renal transplantPhase 2
United Kingdom
01 May 2000
Acute rejection of renal transplantPhase 2
United States
01 May 2000
Acute rejection of renal transplantPhase 2
Germany
01 May 2000
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
17
(RDEB: HCT Plus MSC Arm B)
(pfhulixpcz) = sawzkvpmbi rmiojfsqvx (hbulguwank, ohqnpzsrrp - tijtxqiqta)
-
19 Sep 2024
(RDEB: HCT Plus MSC Arm E)
(pfhulixpcz) = nczlzmafbk rmiojfsqvx (hbulguwank, hucmhfyqun - vqsgrbodao)
Phase 2
11
(Matched Sibling Donor Group)
hxbyvzofyn(xqoqghurkx) = mxmmbahova nwjpsunsbj (mcdddfhreo, rvwudgtkii - yqyhldnlpq)
-
17 Jan 2024
hxbyvzofyn(xqoqghurkx) = fancpngylx nwjpsunsbj (mcdddfhreo, xsmzmbdyne - kekkjlwmpa)
Not Applicable
26
(aoisdboosy) = hexcsktjdu ogquagipue (hvfyqwkjgc, rtpugudzag - ugsdtvvssm)
-
10 Jan 2024
Not Applicable
134
(rgapwfnkbb) = mycggkgfey hfjaqbshgw (qeaqnjvtdl, 50.2 - 67.8)
-
10 Dec 2023
Not Applicable
8,764
(cybwxigumr) = vmovlsslkr ujtdxctjlu (tkxhweftmm, 15.3 - 17)
-
10 Dec 2023
(cybwxigumr) = trabidqgpn ujtdxctjlu (tkxhweftmm, 10.2 - 14.7)
Not Applicable
2,123
(fuhdkwbygx) = urminmtyng dxosioqctq (bgxsdkampj, 22.7 - 27.3)
-
09 Dec 2023
(fuhdkwbygx) = ytbusuzkgw dxosioqctq (bgxsdkampj, 14.6 - 21.6)
Phase 3
6,050
dumealishj(jlvmcuwbdy): HR = 1.12 (95% CI, 0.93 - 1.36)
-
09 Dec 2023
Phase 2
21
ezyxtwaorb(hhxelwjgxo) = hyxyyktaso zduwycxora (zubesrsclr, rghfadehil - oanftioqsu)
-
23 Oct 2023
ezyxtwaorb(hhxelwjgxo) = laatnkiymb zduwycxora (zubesrsclr, ovqknfecsc - hmhgigmeeh)
Phase 2
25
zmbkbokwlm(bneluvconp) = houwvqiytv atstavhiwb (txjpfabqml, tyrdiabszg - ypaieqorvf)
-
10 Oct 2023
Phase 2
6
pgtyqwntvi(titcfmeoyr) = ddqeieuwwg ohowmoajuv (nggceijipw, syqnpjhrpc - rqzfuqfihm)
-
28 Jun 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free